GICS Sector : Healthcare
Stereotaxis, Inc.designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Stereotaxis reported revenue of $7.5 million for Q3 2025, comprising $1.9 million in system revenue and $5.6 million in recurring revenue. The company's gross margin was 55%, with recurring revenue gross margin at 67% and system gross margin at 19%. The operating expenses were $10.7 million, resulting in an operating loss of $6.6 million. The actual EPS loss was $0.03, which was better than the estimated loss of $0.06.
Publication Date: Nov -30
The company made significant progress on the commercial front, receiving orders for 2 Genesis robots expected to be installed in the first half of 2026, adding to the existing system backlog of over $10 million. The FDA approval of the GenesisX system was a landmark event, and a limited launch is underway. The company is transitioning to a full launch pending MAGiC approval in the U.S. and is ramping up manufacturing. As the CFO mentioned, "the MAGiC approval process is progressing well, with interactions with the FDA going smoothly, and no impact from the recent government shutdown."
The company's recurring revenue grew driven by sales of Map-iT catheters, MAGiC ablation catheters, and MAGiC Sweep high-density mapping catheters. The MAGiC Sweep catheter generated over $300,000 in revenue in the first 2 months post-launch. The company expects sustained growth of both systems and recurring revenue through 2026, with quarterly revenue expected to surpass an average of $10 million per quarter.
The company expects Q4 2025 revenue to exceed $9 million, representing over 20% annual revenue growth for 2025. For 2026, the revenue mix is expected to be 30-50% system revenue and 50-70% recurring revenue. Analysts estimate next year's revenue growth at 30.0%. With a current P/S Ratio of 7.61 and EV/EBITDA of -9.76, the market is pricing in significant growth expectations. The ROE and ROIC are negative, indicating that the company is still in an investment phase.
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
Nov -24
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
Nov -13
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Nov -12
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
Nov -11
Stereotaxis Reports 2025 Third Quarter Financial Results
Nov -11
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
Nov -10
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
Oct -21
Stereotaxis (NYSEAMERICAN:STXS) Stock Price Up 3.7% – What’s Next?
Oct -21
Stereotaxis, Inc.'s 8.37% growth in Disposables, Service, and Accessories is driven by increasing adoption of robotic navigation in electrophysiology procedures, growing demand for minimally invasive treatments, and expansion into new geographies. Additionally, the company's focus on innovation, customer support, and strategic partnerships contributes to its growth momentum.
Stereotaxis, Inc.'s 8.9% growth is driven by increasing adoption of robotic navigation systems in electrophysiology, rising demand for minimally invasive procedures, and expanding presence in emerging markets. Additionally, strategic partnerships, innovative product offerings, and growing physician acceptance of robotic-assisted ablation procedures contribute to the company's growth momentum.
A magnetic navigation system for cardiac ablation procedures, providing precise and stable catheter navigation.
A radiofrequency ablation system for cardiac ablation procedures, providing precise and controlled energy delivery.
A remote catheter navigation system for cardiac ablation procedures, providing precise and stable catheter navigation.
A data management and analytics platform for electrophysiology labs, providing insights and workflow optimization.
The threat of substitutes for Stereotaxis, Inc. is moderate due to the presence of alternative medical technologies and treatments.
The bargaining power of customers is low due to the specialized nature of Stereotaxis' products and services, which limits customer negotiating power.
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for Stereotaxis' components and materials.
The threat of new entrants is low due to the high barriers to entry in the medical technology industry, including regulatory hurdles and significant capital requirements.
The intensity of rivalry is high due to the competitive nature of the medical technology industry, with multiple established players competing for market share.
| Value | |
|---|---|
| Debt Weight | 20.03% |
| Debt Cost | 3.95% |
| Equity Weight | 79.97% |
| Equity Cost | 10.69% |
| WACC | 9.34% |
| Leverage | 25.05% |
Value: 7.8
Growth: 2.7
Quality: 4.5
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 9.4
Growth: 0.6
Quality: 3.9
Yield: 0.0
Momentum: 6.5
Volatility: 3.7
1-Year Total Return ->
Value: 4.4
Growth: 4.7
Quality: 4.7
Yield: 0.0
Momentum: 6.5
Volatility: 3.0
1-Year Total Return ->
Value: 6.2
Growth: 1.7
Quality: 3.7
Yield: 0.0
Momentum: 9.0
Volatility: 2.3
1-Year Total Return ->
Value: 3.0
Growth: 6.8
Quality: 2.3
Yield: 0.0
Momentum: 4.0
Volatility: 3.0
1-Year Total Return ->
Value: 8.6
Growth: 4.4
Quality: 3.9
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->